Back

FcRn-mediated antibody recycling drives plaque vulnerability in symptomatic atherosclerosis

29 August 2026 (08:15 - 09:00)
Organised by: Logo
Congress Presentation Part of: Atherosclerosis: molecular mechanisms and therapeutic targets Leukocytes, Inflammation, Immunity ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Ms Shiying Lin

Karolinska Institute, Stockholm (Sweden)

5 More presentations in this session

Presentation thumbnail
Macrophage-derived HB-EGF activates EGFR signaling to impair atherogenic macrophage–vascular smooth muscle cell crosstalk in ASCVD
Doctor A. Scalco (Baltimore, US)
Abstract Slides
Presentation thumbnail
Cholesterol-metabolizing eubacterium ramulus bacteria mitigate vascular senescence and atherosclerosis
Doctor K. Shabanian (Schlieren, CH)
Abstract Slides
Presentation thumbnail
Chronic sympathetic activation decreases atherosclerotic inflammation by regulating β3AR/p-CREB/SFRP5 in perivascular adipose tissue
Doctor Y. Yu (Shanghai, CN)
Abstract Slides
Presentation thumbnail
Modulating atherosclerotic plaque formation by targeting plasminogen receptor PlgRKT
Doctor J. Kral-Pointner (Vienna, AT)
Abstract Slides
Presentation thumbnail
TMEM106B alters vascular smooth muscle cell phenotypes and lysosomal function leading to atherosclerosis
Doctor C. Abrahamian (Munich, DE)
Abstract Slides

Access the full session

Session thumbnail
Atherosclerosis: molecular mechanisms and therapeutic targets

The Event

Event poster

ESC Congress 2026

29 August 2026 08:15 CET
You may be interested in
thumbnail
Congress Presentation
Deletion of the asialyloglycoprotein receptor-1 (ASGR1) causes atheroprotective effects in vitro and in vivo
30 August 2024
thumbnail
Congress Session
Decoding plaque vulnerability: inflammation, lipoproteins, and intracoronary imaging insights
29 August 2026
thumbnail
Congress Presentation
Immune checkpoint inhibition increases aortic inflammation on 18F-FDG PET/CT: a retrospective cohort study in patients with Merkel cell carcinoma receiving avelumab
21 June 2025
thumbnail
Congress Presentation
Autoantibodies directed against apolipoprotein-a-1 as a potential contributor to non-alcoholic fatty liver disease
27 August 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources